The Institute of Molecular Genetics in Moscow synthesized both peptides in the 1980s and 1990s. Russian pharmaceutical companies commercialized them. Russian regulatory authorities approved them for clinical use. Russian military and space programs employed them.
Western research largely ignored them.
This geographic concentration of research activity creates an unusual situation where two peptides have decades of clinical use in one country while remaining essentially unknown in Western medical and research contexts. The knowledge gap works both ways: Russian research proceeded without engaging Western scientific discourse, while Western researchers missed potentially valuable neuropeptide biology.
Molecular Origins: Tuftsin and ACTH
Selank is a synthetic analog of tuftsin, a tetrapeptide (Thr-Lys-Pro-Arg) produced by enzymatic cleavage of the Fc portion of IgG antibodies in the spleen. Natural tuftsin modulates immune function, particularly phagocyte activity. Russian researchers, led by Inna Uchakina and colleagues, extended the sequence and modified it to create a more stable, blood-brain-barrier-permeable analog with anxiolytic properties.
The final Selank sequence is seven amino acids: Thr-Lys-Pro-Arg-Pro-Gly-Pro.
The additional Pro-Gly-Pro sequence enhances resistance to enzymatic degradation while preserving and potentially amplifying the neurological effects observed with tuftsin analogs. The peptide doesn't strongly resemble classical neurotransmitters or neuromodulators, which initially made its mechanism of action puzzling to researchers.
Semax derives from adrenocorticotropic hormone (ACTH), specifically a fragment corresponding to amino acids 4-10 of the ACTH molecule: Met-Glu-His-Phe-Pro-Gly-Pro. This sequence represents part of ACTH's N-terminal region, which contains the melanocortin receptor-binding domain responsible for stimulating cortisol release.
The Semax fragment doesn't activate melanocortin receptors or stimulate cortisol production at typical research doses. Instead, it exhibits cognitive and neuroprotective effects that appear mechanistically distinct from ACTH's endocrine functions.
Ashmarin and colleagues at the Institute of Molecular Genetics characterized Semax through the 1990s, work published primarily in Russian journals with some English-language abstracts. Their research positioned it as a nootropic peptide with potential applications in cognitive enhancement and stroke recovery.
Anxiolytic vs Nootropic Profiles
Selank research emphasizes anxiolytic effects. Studies in rodent anxiety models (elevated plus maze, open field tests, conflict situations) show the peptide reduces anxiety-like behaviors without the sedation or motor impairment characteristic of benzodiazepines.
The mechanism likely involves modulation of the GABAergic system, though not through direct GABA receptor agonism.
Research published by Kozlovskaya et al. in Neuroscience and Behavioral Physiology (2003) demonstrated that Selank increases brain-derived neurotrophic factor (BDNF) expression in rat hippocampus and prefrontal cortex. BDNF plays critical roles in neuroplasticity, stress resilience, and emotional regulation. Whether BDNF upregulation represents the primary mechanism or a downstream effect remains uncertain.
The peptide also influences monoamine metabolism. Studies show alterations in serotonin and dopamine turnover in specific brain regions, though the pattern differs from classical antidepressants or anxiolytics. Some research suggests effects on enkephalin systems and opioid peptide metabolism, adding additional mechanistic complexity.
Semax research focuses on cognitive enhancement and neuroprotection. Animal studies demonstrate improved learning in various paradigm (spatial memory tasks, passive avoidance, conditioned responses). The effects appear to involve enhanced attention and information processing rather than direct memory consolidation improvements.
Neuroprotection studies show Semax reduces infarct size in experimental stroke models and promotes functional recovery. This work, published by Gusev and Skvortsova in Russian journals in the late 1990s, formed the basis for clinical trials in acute ischemic stroke.
The cognitive effects might relate to Semax's influence on BDNF expression, which has been demonstrated in multiple studies. Like Selank, Semax increases BDNF levels in hippocampus and cortex, though the time course and magnitude differ between the peptides.
Semax also modulates the enkephalin system, influences dopaminergic neurotransmission, and affects expression of various neurotrophic factors beyond BDNF. The complexity of these effects makes pinpointing a single "mechanism" challenging.
BDNF Modulation: A Shared Pathway
Both peptides reliably increase BDNF expression in research models, though through potentially distinct mechanisms. This shared effect is notable given their different molecular origins and overall pharmacological profiles.
BDNF supports neuronal survival, promotes synaptic plasticity, and plays key roles in learning and memory. Reduced BDNF expression associates with depression, anxiety, and neurodegenerative conditions in human studies. Interventions that increase BDNF (exercise, certain antidepressants, environmental enrichment) generally support brain health.
Whether exogenous peptides that increase BDNF produce clinically meaningful effects in humans remains an open question.
Animal studies clearly demonstrate the BDNF increase, typically measuring mRNA expression or protein levels in specific brain regions after acute or chronic peptide administration. The functional consequences of these increases, particularly when peptides are administered peripherally, depend on peptide penetration into the CNS and the magnitude and duration of BDNF elevation achieved.
Some research suggests Selank and Semax modulate BDNF indirectly through effects on neurotransmitter systems that regulate BDNF gene transcription. The TrkB receptor, BDNF's primary receptor, activates signaling cascades including MAPK and PI3K pathways that influence numerous cellular processes. Peptide-induced changes in neuronal activity patterns could alter BDNF expression through these activity-dependent mechanisms.
Russian Clinical Approvals and Medical Use
Selank received regulatory approval in Russia in 2009 for anxiety disorders and neurasthenia. It's prescribed as intranasal drops, with typical treatment courses of 14-30 days. The approval was based on clinical trials conducted in Russia involving several hundred patients, demonstrating anxiolytic efficacy comparable to benzodiazepines but with superior tolerability and lack of dependence.
These trials haven't been published in major international English-language journals, limiting Western researchers' ability to evaluate the evidence rigorously. Abstracts and Russian-language publications describe the studies, but full methodological details and raw data remain largely inaccessible to non-Russian-speaking researchers.
Semax has been approved in Russia since the mid-1990s for multiple indications including stroke recovery, traumatic brain injury, cognitive impairment, and attention disorders. Like Selank, it's administered intranasally, though injection formulations also exist for acute conditions.
Clinical use in Russia spans decades, with millions of patient exposures. This real-world experience provides informal safety data, though systematic post-marketing surveillance data hasn't been comprehensively published in international literature.
The Russian medical system's acceptance of these peptides contrasts sharply with their absence from Western pharmacopeias. This reflects different regulatory frameworks, research traditions, and evidence standards rather than necessarily indicating the peptides are ineffective or unsafe.
Intranasal Administration: Research and Rationale
Both peptides employ intranasal delivery in most research and clinical applications. This route offers several theoretical advantages for neuropeptides: bypassing hepatic first-pass metabolism, avoiding gastrointestinal degradation, and potentially providing direct transport to the CNS via olfactory and trigeminal nerve pathways.
The nasal mucosa contains extensive vasculature and sits anatomically close to the brain. Small molecules and peptides can potentially reach the CNS through several routes after intranasal administration: transcellular transport across olfactory epithelium, paracellular transport between epithelial cells, or absorption into systemic circulation followed by crossing the blood-brain barrier.
Research on intranasal peptide delivery suggests the route can enhance CNS bioavailability for certain compounds. Studies with other neuropeptides like insulin and oxytocin show central effects after intranasal administration that occur rapidly relative to intravenous delivery, supporting direct nose-to-brain transport.
Whether Selank and Semax achieve significant CNS concentrations through this route hasn't been definitively established with direct measurement in humans. Animal studies using radiolabeled peptides provide some supporting evidence, but species differences in nasal anatomy and blood-brain barrier characteristics complicate extrapolation.
The peptides do show biological activity when administered intranasally in research models and human studies, but distinguishing central from peripheral mechanisms remains challenging. Peripheral effects on immune function, stress hormone regulation, or other systems could theoretically produce changes in behavior and cognition without requiring direct CNS penetration.
The Western Research Gap
Searching PubMed for "Selank" returns approximately 40 papers, most from Russian authors. "Semax" yields around 80. For comparison, "BPC-157" returns over 100, and that peptide is also predominantly researched outside mainstream Western pharmaceutical development.
This limited Western engagement reflects several factors: publication in Russian-language journals that aren't indexed in major databases, focus on clinical applications rather than mechanistic investigation, and lack of commercial development in Western markets that would fund research.
The situation creates challenges. Russian research might have identified valuable neuropeptide biology that Western researchers are reinventing or missing entirely. Conversely, the research might not meet the methodological rigor expected in Western scientific contexts, making it difficult to evaluate robustness of findings.
Language barriers compound the problem. Automated translation tools help, but scientific terminology and nuanced methodology descriptions often suffer in translation. Researchers who could build on Russian findings often can't access or evaluate the primary literature effectively.
Some Western research groups have begun investigating these peptides. Publications appear in journals like Behavioral Brain Research and Neuropeptides, often authored by international collaborations including Russian scientists. This gradual integration into mainstream neuroscience research might eventually clarify the peptides' true potential and limitations.
Comparison and Potential Research Applications
Selank seems better suited for research on anxiety, stress response, and emotional regulation. Its GABA-ergic and enkephalinergic effects distinguish it from Semax's more dopaminergic and attention-related profile.
Semax appears more appropriate for cognitive enhancement studies, neuroprotection research, and investigation of recovery from neurological injury. Its faster onset and shorter duration of action (hours rather than days) might also make it preferable for acute intervention studies.
Both peptides offer research value for:
- BDNF regulation mechanisms
- Non-traditional anxiolytic and nootropic pathways
- Intranasal peptide delivery optimization
- Comparative neuropeptide pharmacology
Neither replaces the need for mechanistic understanding. The complexity of their effects across multiple neurotransmitter and neurotrophic systems means interpreting results requires careful experimental design and controls.
Safety Considerations and Knowledge Limits
Decades of clinical use in Russia without reported major safety concerns provides some reassurance, though systematic safety surveillance data hasn't been rigorously published. The peptides appear generally well-tolerated at recommended doses, with side effects typically limited to mild nasal irritation (intranasal route) or injection site reactions.
Long-term safety data remains limited even in Russian literature. Effects of chronic use beyond several months haven't been systematically studied. Potential interactions with other neuropsychiatric medications require investigation.
The mechanisms remain incompletely understood despite decades of research. Multiple proposed mechanisms might all contribute, or some might reflect secondary effects rather than primary actions. This mechanistic uncertainty complicates predicting behavior in new contexts or populations.
Human research outside Russia is minimal. The peptides' effects might differ in populations with different genetic backgrounds, dietary patterns, environmental exposures, or baseline health characteristics. Assuming Russian clinical experience fully translates requires caution.
Two Peptides, One Question
The question Selank and Semax pose isn't whether they work. Decades of Russian research and clinical use suggest they produce some effects, at minimum. The question is what those effects mean, how they occur, and whether they offer advantages over existing approaches to anxiety and cognitive enhancement.
Answering requires bridging the research gap between Russian and Western scientific traditions. Until that happens, these remain peptides with intriguing biology, suggestive evidence, and uncertain potential.
The research continues, gradually, in both Moscow and elsewhere.